Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 279

1.

Up-regulation of ribosomal genes is associated with a poor response to azacitidine in myelodysplasia and related neoplasms.

Monika Belickova M, Merkerova MD, Votavova H, Valka J, Vesela J, Pejsova B, Hajkova H, Klema J, Cermak J, Jonasova A.

Int J Hematol. 2016 Jul 14. [Epub ahead of print]

PMID:
27416819
2.

Time-dependent changes in mortality and transformation risk in MDS.

Pfeilstöcker M, Tuechler H, Sanz G, Schanz J, Garcia-Manero G, Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Malcovati L, Cazzola M, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Levis A, Luebbert M, Maciejewski J, Machherndl-Spandl S, Magalhaes SM, Miyazaki Y, Sekeres MA, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, Van de Loosdrecht AA, Germing U, Haase D, Greenberg PL.

Blood. 2016 Jun 22. pii: blood-2016-02-700054. [Epub ahead of print]

PMID:
27335276
3.

TP53 mutation variant allele frequency is a potential predictor for clinical outcome of patients with lower-risk myelodysplastic syndromes.

Belickova M, Vesela J, Jonasova A, Pejsova B, Votavova H, Merkerova MD, Zemanova Z, Brezinova J, Mikulenkova D, Lauermannova M, Valka J, Michalova K, Neuwirtova R, Cermak J.

Oncotarget. 2016 May 6. doi: 10.18632/oncotarget.9200. [Epub ahead of print]

4.

Molecular Characterization of β-Thalassemia in the Czech and Slovak Populations: Mediterranean, Asian and Unique Mutations.

Divoka M, Partschova M, Kucerova J, Mojzikova R, Cermak J, Pospisilova D, Fabryova V, Prochazkova D, Indrak K, Divoky V.

Hemoglobin. 2016 Jun;40(3):156-62. doi: 10.3109/03630269.2016.1152581. Epub 2016 Mar 9.

PMID:
26956563
5.

Disulfide subproteome alterations in the platelets of patients with myelodysplastic syndrome.

Pecankova K, Majek P, Cermak J, Dyr JE.

J BUON. 2015 Nov-Dec;20(6):1643-4. No abstract available.

PMID:
26854469
6.

Copy number neutral loss of heterozygosity at 17p and homozygous mutations of TP53 are associated with complex chromosomal aberrations in patients newly diagnosed with myelodysplastic syndromes.

Svobodova K, Zemanova Z, Lhotska H, Novakova M, Podskalska L, Belickova M, Brezinova J, Sarova I, Izakova S, Lizcova L, Berkova A, Siskova M, Jonasova A, Cermak J, Michalova K.

Leuk Res. 2016 Mar;42:7-12. doi: 10.1016/j.leukres.2016.01.009. Epub 2016 Jan 24.

PMID:
26851439
7.

Molecular cytogenetic analysis of dicentric chromosomes in acute myeloid leukemia.

Sarova I, Brezinova J, Zemanova Z, Ransdorfova S, Izakova S, Svobodova K, Pavlistova L, Berkova A, Cermak J, Jonasova A, Siskova M, Michalova K.

Leuk Res. 2016 Apr;43:51-7. doi: 10.1016/j.leukres.2016.01.001. Epub 2016 Jan 8.

PMID:
26821593
8.

[Lenalidomide treatment in myelodysplastic syndrome with 5q deletion--Czech MDS group experience].

Jonášová A, Červinek L, Bělohlávková P, Čermák J, Beličková M, Rohoň P, Černá O, Hochová I, Šišková M, Kačmářová K, Janoušová E.

Vnitr Lek. 2015 Dec;61(12):1028-33. Czech.

PMID:
26806497
9.

Biocompatible Size-Defined Dendrimer-Albumin Binding Protein Hybrid Materials as a Versatile Platform for Biomedical Applications.

Maly J, Stanek O, Frolik J, Maly M, Ennen F, Appelhans D, Semeradtova A, Wrobel D, Stofik M, Knapova T, Kuchar M, Stastna LC, Cermak J, Sebo P, Maly P.

Macromol Biosci. 2016 Apr;16(4):553-66. doi: 10.1002/mabi.201500332. Epub 2016 Jan 8.

PMID:
26748571
10.

Plasma Protein Biomarker Candidates for Myelodysplastic Syndrome Subgroups.

Majek P, Pecankova K, Cermak J, Dyr JE.

Biomed Res Int. 2015;2015:209745. doi: 10.1155/2015/209745. Epub 2015 Sep 13.

11.

VATS lobectomy, history, indication, contraindication and general techniques.

Hytych V, Horazdovsky P, Pohnan R, Pracharova S, Taskova A, Konopa Z, Cernovska M, Demes R, Cermak J, Vasakova M, Benej R.

Bratisl Lek Listy. 2015;116(7):400-3.

PMID:
26286240
12.

Peripheral blood mononuclear cell proteome changes in patients with myelodysplastic syndrome.

Pecankova K, Majek P, Cermak J, Dyr JE.

Biomed Res Int. 2015;2015:872983. doi: 10.1155/2015/872983. Epub 2015 Apr 16.

13.

Retinol binding protein 4 plasma level in myelodysplastic syndrome subgroups.

Majek P, Pecankova K, Cermak J, Gasova Z, Dyr JE.

Int J Lab Hematol. 2015 Oct;37(5):e127-8. doi: 10.1111/ijlh.12377. Epub 2015 May 6. No abstract available.

PMID:
25945923
14.

BCL11A deletions result in fetal hemoglobin persistence and neurodevelopmental alterations.

Basak A, Hancarova M, Ulirsch JC, Balci TB, Trkova M, Pelisek M, Vlckova M, Muzikova K, Cermak J, Trka J, Dyment DA, Orkin SH, Daly MJ, Sedlacek Z, Sankaran VG.

J Clin Invest. 2015 Jun;125(6):2363-8. doi: 10.1172/JCI81163. Epub 2015 May 4.

15.

Validation of the revised international prognostic scoring system (IPSS-R) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registry.

de Swart L, Smith A, Johnston TW, Haase D, Droste J, Fenaux P, Symeonidis A, Sanz G, Hellström-Lindberg E, Cermák J, Germing U, Stauder R, Georgescu O, MacKenzie M, Malcovati L, Holm MS, Almeida AM, Mądry K, Slama B, Guerci-Bresler A, Sanhes L, Beyne-Rauzy O, Luño E, Bowen D, de Witte T.

Br J Haematol. 2015 Aug;170(3):372-83. doi: 10.1111/bjh.13450. Epub 2015 Apr 24.

PMID:
25907546
16.

Aberrant expression of the microRNA cluster in 14q32 is associated with del(5q) myelodysplastic syndrome and lenalidomide treatment.

Krejčík Z, Beličková M, Hruštincová A, Kléma J, Zemanová Z, Michalová K, Čermák J, Jonášová A, Dostálová Merkerová M.

Cancer Genet. 2015 Apr;208(4):156-61. doi: 10.1016/j.cancergen.2015.03.003. Epub 2015 Mar 12.

PMID:
25883014
17.

Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM).

Della Porta MG, Tuechler H, Malcovati L, Schanz J, Sanz G, Garcia-Manero G, Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Levis A, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Krieger O, Luebbert M, Maciejewski J, Magalhaes SM, Miyazaki Y, Pfeilstöcker M, Sekeres MA, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Germing U, Haase D, Greenberg PL, Cazzola M.

Leukemia. 2015 Jul;29(7):1502-13. doi: 10.1038/leu.2015.55. Epub 2015 Feb 27.

PMID:
25721895
18.

Post hoc analysis of the relationship between baseline white blood cell count and survival outcome in a randomized Phase III trial of decitabine in older patients with newly diagnosed acute myeloid leukemia.

Arthur C, Cermak J, Delaunay J, Mayer J, Mazur G, Thomas X, Wierzbowska A, Jones MM, Berrak E, Kantarjian H.

J Blood Med. 2015 Jan 8;6:25-9. doi: 10.2147/JBM.S64067. eCollection 2015.

19.

High numbers of mobilized CD34+ cells collected in AML in first remission are associated with high relapse risk irrespective of treatment with autologous peripheral blood SCT or autologous BMT.

Hengeveld M, Suciu S, Chelgoum Y, Marie JP, Muus P, Lefrère F, Mandelli F, Pane F, Amadori S, Fioritoni G, Labar B, Baron F, Cermak J, Bourhis JH, Storti G, Fazi P, Hagemeijer A, Vignetti M, Willemze R, de Witte T.

Bone Marrow Transplant. 2015 Mar;50(3):341-7. doi: 10.1038/bmt.2014.262. Epub 2014 Nov 17.

PMID:
25402418
20.

Acetone-induced polymerization of 3-aminopropyltrimethoxysilane (APTMS) as revealed by NMR spectroscopy – revisited.

Schraml J, Korec S, Krump M, Čermák J.

Magn Reson Chem. 2015 Feb;53(2):154-9. doi: 10.1002/mrc.4171. Epub 2014 Oct 22. No abstract available.

PMID:
25335777
Items per page

Supplemental Content

Loading ...
Write to the Help Desk